CytRx Unable to File Q1 Results on Schedule
CytRx said this week that it is unable to file its first-quarter financial results with the US Securities and Exchange Commission on schedule.
In an SEC filing, CytRx said it is unable to file the report "due to its further review and assessment … of the company's stock options and possible adjustments to the pro forma disclosures in the stock-based compensation footnote to the company's financial statements."
CytRx did not provide an estimate as to when it would be able to file its financial results.
Qiagen Sets First RNAi User Forum Meeting for June
Qiagen has scheduled the first meeting of its High-Throughput RNAi User Forum for June 8 in Boston.
The company established the forum earlier this year in order to help researchers design and run RNAi-based screening experiments (see RNAi News, 3/30/2006).
According to Qiagen, the meeting will provide an opportunity to exchange information with fellow scientists and researchers working in the field of high-throughput RNAi.
Additional details can be found on Qiagen's corporate website.
Sirna Plans 10-Million-Share Public Offering
Sirna Therapeutics this week announced that it is planning a public offering of 10 million shares of its stock.
According to Sirna, it is offering 8 million shares. The other 2 million are being offered by institutional investors Oxford Bioscience Partners, The Sprout Group, and Venrock Associates.
The underwriters of the offering will be granted a 30-day option to purchase an additional 1.5 million shares form both Sirna and the institutional investors to cover over-allotments
CIC bioGUNE Joins Open Biosystems' Open Access RNAi Program
Open Biosystems said last week that Centro de Investigación Cooperativa en Biociencias, a Spanish research institute established by public and private institutions, has joined the company's Open Access RNAi Program.
The program was established by Open Biosystems in order to make its genome-wide shRNA libraries more affordable for the company's academic customer base (see RNAi News, 2/2/2006).
According to Open Biosystems, CIC bioGUNE has purchased the company's whole-genome human retroviral shRNAmir library through the program.
Upstate to Sell Galapagos' Adenovirus Products; Could Play in siRNA Market
Upstate, a subsidiary of Serologicals, will market and sell Galapagos' adenovirus products worldwide, excluding Japan, Galapagos said this week.
In return, Galapagos will receive double-digit royalties on net sales.
A hallmark of the adenovirus technology is the stability of the knock-in and knock-down protein levels, and the suitability for high-throughput assays using human primary cells, Upstate said.
These features should allow the adenovirus technology to compete effectively in the global market for siRNA reagents. Galapagos retains rights to continue servicing its existing customers for these products.
Devgen, DuPont Extend Research Agreement on Pest-Resistant Crops
DuPont subsidiary Pioneer Hi-Bred International and Devgen have extended a research collaboration aimed at developing nematode-resistant crops, the firms said this week.
Devgen will receive research payments and it is eligible for milestones and royalties, the companies said.
Devgen will use its technology to identify and express genes useful to plant resistance to nematodes, and Pioneer will incorporate the findings into new crop varieties, the companies added.
Devgen's technology uses gene knockdown approaches, including RNAi, in C. elegans to identify and validate drug targets, determine compounds' mechanisms of action, and develop RNAi-based transgenic crops.